We create innovative treatments for nervous system damage due to injury or disease.
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company creating innovative treatments that enable the nervous system to repair itself following damage. NervGen’s lead drug candidate, NVG-291 is currently in a Phase 1 clinical trial. The company’s initial target indications are spinal cord injury, Alzheimer’s disease and multiple sclerosis.
Subscribe to our mailing list to stay up to date
November 17, 2022
NervGen reported the US Patent and Trade Office issued US Patent No. 11,497,812 B2 Compositions and Methods for Inhibiting the Activity of LAR Family Phosphatases to Case Western Reserve University.
October 24, 2022
NervGen Pharma featured in Health Europa article outlining how NervGen is exploring approaches to Alzheimer’s treatment culminating in its own novel method for treating nervous system damage using the revolutionary NVG-291 drug.
February 11, 2022
Interview with Paul Brennan, NervGen President & CEO (Interview at 29:22 in video)